Journal
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 21, Issue 1, Pages 245-249Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2010.11.026
Keywords
[C-11]SB-216763; Glycogen synthase kinase-3 (GSK-3); Radiosynthesis; Positron emission tomography (PET); Cancer; Alzheimer's disease
Categories
Funding
- Breast Cancer Research Foundation of Indiana University
- Indiana Genomics Initiative (INGEN) of Indiana University
- Lilly Endowment Inc.
- NSF-MRI [CHE-0619254]
Ask authors/readers for more resources
SB-216763 is a novel, potent and selective glycogen synthase kinase-3 (GSK-3) inhibitor with an IC50 value of 34 nM. [C-11]SB-216763 (3-(2,4-dichlorophenyl)-4-(1-[C-11]methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione), a new potential PET agent for imaging of GSK-3, was first designed and synthesized in 20-30% decay corrected radiochemical yield and 370-555 GBq/mu mol specific activity at end of bombardment (EOB). The synthetic strategy was to prepare a carbon-11-labeled maleic anhydride intermediate followed by the conversion to maleimide. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available